LIFE SCIENCES BPO MARKET ANALYSIS
Global life sciences BPO market is estimated to be valued at USD 408.1 Bn in 2024 and is expected to reach USD 972.2 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031.
Discover market dynamics shaping the industry request sample copy
Global life sciences BPO market growth is driven by increasing research and development expenditure globally and rising reliance on outsourcing of non-core functions by pharmaceutical and biotech companies. Growing awareness for cost control alongside focus on expansion of manufacturing capabilities and services has encouraged market players to outsource business processes to third-party life sciences BPO providers. Furthermore, life sciences BPO’s bring opportunities to leverage location and technology advantages from their global network to increase efficiencies and optimize costs. This helps research organizations to focus more on their core functions and pipelines.
Rising Cost of Clinical Trials
With rising R&D spending in the pharmaceutical and biotech industry, the costs associated with clinical drug trials have also exponentially increased. Clinical trials have become lengthy and complex procedures involving thousands of patients enrolled across hundreds of sites worldwide. The management of these large-scale clinical operations requires specialized skills and expertise that many biopharma companies lack in-house. Outsourcing non-core functions like patient recruitment and retention, site management, laboratory sample testing, and clinical data management to specialist BPO providers has become increasingly attractive as it allows biopharma companies to focus on their core drug development work. By outsourcing clinical trial processes, biopharma sponsors can achieve significant cost savings estimated to be around 30-50% compared to doing trials in-house. This leads to increased adoption of life sciences BPO services.
Get actionable strategies to beat competition: Get instant access to report
Regulatory Compliance and Data Security
Regulators across the world are placing greater scrutiny on clinical trial conduct and are imposing stricter rules for data privacy, integrity, and security. From the FDA to the EMA to Japan's PMDA, regulators are ramping up GXP inspections and enforcing heavy penalties for non-compliance issues. The regulatory landscape in life sciences has become highly complex with a plethora of global guidelines and directives that sponsors must adhere. Ensuring full compliance and maintaining customizable systems for safety reporting, document control, and auditing is challenging for most biopharma companies. By leveraging BPO providers that have extensive regulatory expertise and technology-enabled platforms, sponsors can address compliance in a more efficient, low risk manner. Furthermore, using specialist third-party administrators allows life sciences companies to focus on their core research while ensuring patient privacy and data security is handled by partners with world-class infrastructure.
Key Takeaways from Analyst-
Global life sciences BPO market growth is driven by increasing R&D expenditure and complex regulatory requirements. Pharmaceutical companies are outsourcing non-core activities to achieve cost savings and focus on core competencies. Asia Pacific region dominated the market due to low-cost skilled resources and is expected to grow fast over the next five years leveraging investments in healthcare infrastructure.
Intellectual property protection and data privacy concerns can pose challenges for the outsourcing model. Stringent regulations also increase compliance requirements for service providers. Limited specialization in niche therapy areas and high employee turnover can also impact service quality. Lack of standardized processes and technology adoption across BPO players can hamper the market growth.
Growing generics market and demand for ancillary services can offer new opportunities. Increasing focus on patient outcomes and real world evidence also boost clinical research outsourcing. Emergence of central laboratories and analytical testing hubs aid outsourcing growth. Adoption of digital technologies like AI, automation, blockchain and analytics streamline operations and improve research productivity. North America and Western Europe are also expanding existing capabilities to cater to global life sciences companies.
Market Challenges: Quality assurance issues
Quality assurance is one of the major concerns hampering the growth of the life sciences BPO market. Life sciences BPO dealing with sensitive patient data and performing critical functions like clinical trials and drug discovery require highest level of accuracy and compliance. Any lapse in quality can put patients' health at risk and also invite huge penalties and litigations for companies. This heavy burden of ensuring top notch quality at every stage act as a deterrent for many pharma and biotech companies from outsourcing their core operations.
Maintaining quality standards across different global locations while managing a distributed workforce is challenging for BPO firms in this industry. These need to implement robust QA mechanisms and meticulous documentation practices to clear regular audits. This increases operational costs and reduces profit margins. In 2021, according to the report from United Nations, 50% of outsourced clinical trials from U.S. faced quality issues including protocol deviations, incomplete record maintenance and misreporting of adverse events. This has severely dented client confidence in outsourcing and driven more work back in-house.
The inherent risks associated make companies wary of relinquishing control of critical functions. Even a small error can lead to delays in drug launch, clinical trial failures or product recalls causing huge financial losses running into millions. This risk avoidance behaviour of pharma companies stagnates the reliance on external partners. Unless BPO players find innovative ways to strengthen quality oversight, assuage security concerns and ensure regulatory adherence at low costs, the life sciences BPO market might face suppressed growth rates compared to other sectors. Improving transparency through technological interventions and upskilling workforce on nuanced quality aspects can help allay many reservations holding back broader adoption of distributed manufacturing and R&D models.
Market Opportunities: New drug discovery & development
Global life sciences BPO market focusing on new drug discovery and development can offer growth opportunities. The process of drug development is very long, complex and capital intensive. It takes 10-15 years for a new drug molecule to be developed, tested and brought to market. The average cost of developing a new drug is estimated to be over US$ 2.6 billion, according to a report by Tufts Center for the Study of Drug Development. This has compelled many large pharmaceutical companies to look at outsourcing non-core activities to specialist CROs and CMOs to reduce costs and timelines. Drug discovery and clinical research are two phases where life sciences companies are deriving significant benefits from outsourcing. As per the analytics by the WHO, over 3,000 clinical trials were outsourced globally to CROs in 2021 across different therapeutic areas. CROs offer advantages of specialized expertise, dedicated facilities, flexible staffing models and geographical presence which can accelerate drug trials. Their advanced analytics capabilities also help pharmaceutical sponsors to identify the right drug candidates faster from the initial pool of molecules. On the discovery side, CROs maintain sophisticated libraries of chemical compounds and screening technologies that assist researchers in selecting lead molecules for development.
Discover high revenue pocket segments and roadmap to it: Get instant access to report
By Service Type: Factors fueling rising dominance of CRO Services in Life Sciences BPO domain
The pharmaceutical outsourcing segment is projected to dominate the market with a 60.12% share in 2024 due to several key factors. Pharmaceutical and biotech companies increasingly outsource clinical trials and related services to Contract Research Organizations (CROs). CROs excel in managing comprehensive aspects of drug development, from early-stage research to post-marketing trials, leveraging their expertise in clinical monitoring, data management, biostatistics, and regulatory compliance. This specialization helps sponsors accelerate development timelines, efficiently navigate complex regulatory landscapes, and optimize resource allocation. By offering end-to-end solutions and access to global patient populations, CROs enhance trial quality and cost-efficiency, making them the preferred partners in the pharmaceutical industry.
By End User: Pharmaceutical Companies: Largest consumer segment in Life Sciences BPO sector
By end user, pharmaceutical companies segment is estimated to contribute the highest market share of 40.12% in 2024. Drug makers continue to outsource non-core functions in order to streamline internal operations and concentrate on high-value strategic activities. Their outsourcing requirements extend across the entire value chain from discovery and pre-clinical testing to commercialization support. Clinical development presents the biggest opportunity due to scale and complexity of trials. Pharma companies partner with CROs to execute global multi-site studies and leverage specialized technical expertise. Manufacturing and quality testing is also increasingly handled by contract manufacturing organizations (CMO) to gain capacity and flexibility. On the commercial front, contract sales organizations (CSO) are engaged for promotional activities in select therapeutic areas and geographical markets. Furthermore, rising R&D costs have accelerated outsourcing of laboratory testing, data management and other non-clinical functions to contract research organizations (CRO). This optimal utilization of external resources enables pharmaceutical sponsors to maximize productivity and innovation in a cost-effective manner.
To learn more about this report, request sample copy
North America dominates the global life sciences BPO market with an estimated market share of 40.2% in 2024. The region is home to well-established pharmaceutical and biotechnology companies that are looking to reduce operating costs through outsourcing non-core functionalities. The presence of large pharmaceutical customer base has attracted leading life sciences BPO vendors to set up facilities across major hubs in the U.S. and Canada. These companies offer a wide range of services from drug discovery and clinical research to regulatory services and commercialization activities.
Stringent regulatory requirements across the development and commercialization process also make these companies open to outsourcing work to specialized third-party providers. The region contributes significantly to the global clinical trials market due to initiatives by governments and private organizations to encourage pharmaceutical R&D. Other factors such as availability of expertise, need for data management and medical writing capabilities have further augmented North America's position as the leading market.
Among emerging regions, Asia Pacific is experiencing strong growth in the life sciences BPO sector. Countries such as India, China, Japan and South Korea are investing heavily in developing their healthcare infrastructure, workforce capabilities and regulatory frameworks. This has attracted life sciences companies globally to start outsourcing non-core functions to the region. India has emerged as the top destination for clinical research and data management services. It has a large English speaking talent pool qualified in sciences, lower costs of operations compared to Western countries and a developing ecosystem of global life sciences vendors.
Life Sciences BPO Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 408.1 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 13.2% | 2031 Value Projection: | US$ 972.2 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Accenture, Plc, Boehringer Ingelheim GmbH, Cognizant Technology Solutions, Infosys, Genpact Limited, ProMab Biotechnologies, Inc, Charles River Laboratories International, Inc, Catalent, Inc., Covance, Inc., Fareva, ICON, Plc, DSM, Health Decisions, Inc., IQVIA, Laboratory Corporation of America Holdings, Syneos Health, Inc., Parexel International Corporation, PRA Health Sciences |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Life Sciences BPO (Business Process Outsourcing) Market consists of outsourcing non-core business functions related to the life sciences industry. This includes services like clinical data management, medical writing, regulatory consulting, sales force outsourcing, and other back-office administrative functions for life sciences companies. By outsourcing these non-core functions to specialized BPO providers, life sciences companies are able to focus internal resources on core areas like R&D, manufacturing, and marketing while reducing costs and improving process efficiencies.
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
